Advertisement

Topics

How A Drugmaker Gamed The System To Keep Generic Competition Away

10:30 EDT 17 May 2018 | Topix

When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month's supply. By the time David Mitchell started taking Revlimid in November 2010, Celgene had bumped the price up to about $8,000 a month.

Original Article: How A Drugmaker Gamed The System To Keep Generic Competition Away

NEXT ARTICLE

More From BioPortfolio on "How A Drugmaker Gamed The System To Keep Generic Competition Away"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...